Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain.

Farina AR, Cappabianca L, Di Ianni N, Ruggeri P, Ragone M, Merolle S, Gulino A, Mackay AR.

FEBS Lett. 2012 Jul 30;586(16):2366-74. doi: 10.1016/j.febslet.2012.05.048. Epub 2012 Jun 4.

4.

Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism.

Monea S, Lehti K, Keski-Oja J, Mignatti P.

J Cell Physiol. 2002 Aug;192(2):160-70.

PMID:
12115722
5.

Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases.

Hahn-Dantona E, Ramos-DeSimone N, Sipley J, Nagase H, French DL, Quigley JP.

Ann N Y Acad Sci. 1999 Jun 30;878:372-87.

PMID:
10415742
6.

Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase.

Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J.

J Biol Chem. 2002 Mar 8;277(10):8440-8. Epub 2002 Jan 4.

8.

Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion.

Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP.

J Biol Chem. 1999 May 7;274(19):13066-76.

9.

Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration.

Cao J, Kozarekar P, Pavlaki M, Chiarelli C, Bahou WF, Zucker S.

J Biol Chem. 2004 Apr 2;279(14):14129-39. Epub 2004 Jan 16.

10.

Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.

Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D.

Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1035-45.

11.
12.

Inhibition of plasmin-mediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5.

Huet E, Cauchard JH, Berton A, Robinet A, Decarme M, Hornebeck W, Bellon G.

Biochem Pharmacol. 2004 Feb 15;67(4):643-54. Erratum in: Biochem Pharmacol. 2004 Mar 1;67(5):1011.

PMID:
14757164
13.

MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells.

Burg-Roderfeld M, Roderfeld M, Wagner S, Henkel C, Grötzinger J, Roeb E.

Int J Oncol. 2007 Apr;30(4):985-92.

PMID:
17332939
14.

uPA/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration.

Legrand C, Polette M, Tournier JM, de Bentzmann S, Huet E, Monteau M, Birembaut P.

Exp Cell Res. 2001 Apr 1;264(2):326-36.

PMID:
11262189
15.

Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3.

Geurts N, Martens E, Van Aelst I, Proost P, Opdenakker G, Van den Steen PE.

Biochemistry. 2008 Feb 26;47(8):2689-99. doi: 10.1021/bi702260q. Epub 2008 Feb 1.

PMID:
18237197
16.

Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.

Lijnen HR, Silence J, Lemmens G, Frederix L, Collen D.

Thromb Haemost. 1998 Jun;79(6):1171-6.

PMID:
9657444
17.

Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia.

Tai SH, Chen HY, Lee EJ, Chen TY, Lin HW, Hung YC, Huang SY, Chen YH, Lee WT, Wu TS.

J Pineal Res. 2010 Nov;49(4):332-41. doi: 10.1111/j.1600-079X.2010.00797.x.

PMID:
20663046
18.

Inhibition of proteases involved in embryo implantation by cholesterol sulfate.

Koizumi M, Momoeda M, Hiroi H, Nakazawa F, Nakae H, Ohno T, Yano T, Taketani Y.

Hum Reprod. 2010 Jan;25(1):192-7. doi: 10.1093/humrep/dep370. Epub 2009 Nov 7.

19.

Nonlysine-analog plasminogen modulators promote autoproteolytic generation of plasmin(ogen) fragments with angiostatin-like activity.

Ohyama S, Harada T, Chikanishi T, Miura Y, Hasumi K.

Eur J Biochem. 2004 Feb;271(4):809-20.

PMID:
14764098
20.

Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9.

Dufour A, Sampson NS, Li J, Kuscu C, Rizzo RC, Deleon JL, Zhi J, Jaber N, Liu E, Zucker S, Cao J.

Cancer Res. 2011 Jul 15;71(14):4977-88. doi: 10.1158/0008-5472.CAN-10-4552. Epub 2011 Jun 6. Erratum in: Cancer Res. 2012 Oct 1;72(19):5141-2. Dosage error in article text.

Items per page

Supplemental Content

Write to the Help Desk